December 5, 2012
SafeCode Drug Technologies Corp. (OTCBB: SAFC)(the "Company"), a developer of patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, is pleased to announced it has identified and is commencing to develop the world's first prototype for its next generation application for Drug Safety Administration. The prototype development and the technology application is expected to be completed within 4-6 months and will be then demonstrated to worldwide major drug container manufacturers for possible adoption to ensure a new generation drug administration safety application.
The Company recently launched its new website which has also been optimized for accessibility and easy navigation on smartphones and tablets as well as laptops and home computers.
In conjunction with the website unveiling, the Company has published a new video demonstrating the SafeCode voice-activation technology as a novel product candidate for the medical industry. Investors are encouraged to view the video on the Company's website or on YouTube at
Across the past month, the Company has been granted eligibility status by the Depository Trust Company and commenced trading on the OTC Bulletin Boards.
"We are dedicated to providing a high-quality product and transparency to our stakeholders. We are taking all necessary steps to meet these corporate goals and doing so in an expeditious manner," said
, Chief Executive Officer at SafeCode Drug Technologies Corp. "Accidental deaths resulting from administering incorrect medication represent a multi-billion-dollar area of unmet need. We believe that we have a solution with our patent-pending voice-recognition technology that will benefit manufacturers, pharmacists and patients while building our corporate value. This is an exciting time for our company and shareholders as we enter the commercialization phase. The new website was important to us as it showcases the SafeCode solution while giving investors fast, user-friendly access to information on our company."
About SafeCode Drug Technologies